OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
16 mrt 2010 - 18:46
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces update on publication of positive interim Locteron Phase IIb data
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO) announces that two further abstracts containing preliminary Locteron® Phase IIb clinical results have just been published. These abstracts were submitted by OctoPlus’ licensee Biolex and have been accepted for poster presentations on 15 April 2010 during the 45th International Liver Congress in Vienna, Austria. The poster presentations at the conference will contain final results from two Phase IIb studies after 12 weeks of treatment with Locteron compared to PEG-Intron®.
Datum laatste update: 21 maart 2025